Taselisib

Content sourced from Wikipedia, licensed under CC BY-SA 3.0.

Taselisib (development code GDC-0032) is a cancer drug candidate that blocks the PI3K enzyme, mainly the p110α variant produced by the PIK3CA gene. It is a small molecule designed to slow or stop cancer cell growth. The drug was developed by Roche. In June 2018, Roche announced that there would be no further development of taselisib after the top-line results of the Phase III Sandpiper study. Trials for patients who were benefiting at the time were allowed to continue, but taselisib is no longer being pursued for new patients.